IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.987
EU - Europa 2.906
AS - Asia 1.015
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 1
SA - Sud America 1
Totale 9.971
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.968
UA - Ucraina 769
IE - Irlanda 456
TR - Turchia 429
SE - Svezia 369
IT - Italia 368
DE - Germania 321
DK - Danimarca 282
SG - Singapore 200
CN - Cina 182
FI - Finlandia 164
KR - Corea 152
GB - Regno Unito 137
CI - Costa d'Avorio 54
IN - India 23
IR - Iran 23
CA - Canada 17
BE - Belgio 14
FR - Francia 8
BA - Bosnia-Erzegovina 6
EU - Europa 6
HK - Hong Kong 4
MX - Messico 2
NL - Olanda 2
A1 - Anonimo 1
AL - Albania 1
AT - Austria 1
AU - Australia 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
ID - Indonesia 1
JP - Giappone 1
LT - Lituania 1
MD - Moldavia 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
RS - Serbia 1
Totale 9.971
Salva come PNG Salva come JPEG
Città #
Jacksonville 794
Fairfield 742
Chandler 537
Dublin 451
Ashburn 356
Wilmington 313
Woodbridge 303
Seattle 252
Houston 245
Boardman 244
Des Moines 242
Cambridge 241
New York 208
Ann Arbor 193
Lawrence 173
Princeton 173
San Mateo 172
Turin 103
San Diego 97
Abidjan 54
Centro 51
Redmond 41
Singapore 35
Beijing 30
London 24
Shanghai 20
Helsinki 18
Norwalk 18
Los Angeles 17
Washington 17
Marche 16
Ottawa 15
Brussels 14
Guangzhou 13
Kilburn 13
Pune 12
Wuhan 12
Bologna 9
Ancona 8
Izmir 8
Milan 8
Bari 7
San Severino Marche 7
Falls Church 6
Ferrara 6
Sarajevo 6
Andover 5
Jinhua 5
Prescot 5
Acton 4
Auburn Hills 4
Chiswick 4
Falconara Marittima 4
Hanover 4
Jiaxing 4
Pesaro 4
Rome 4
Seoul 4
Wuxi 4
Appignano 3
Cingoli 3
Delhi 3
Heze 3
Hounslow 3
Islington 3
Macerata 3
Mountain View 3
Nanjing 3
Paris 3
Porto 3
Squinzano 3
Yiwu 3
Amsterdam 2
Arco 2
Bhopal 2
Cava De' Tirreni 2
Central 2
Conegliano 2
Corridonia 2
Dallas 2
Indore 2
Monterrey 2
Naples 2
Napoli 2
New Bedfont 2
Olgiate Comasco 2
Osimo 2
Quanzhou 2
Rimini 2
Tiantai Chengguanzhen 2
Tolentino 2
Vallefoglia 2
Villafranca Padovana 2
Agliè 1
Ascoli Piceno 1
Atlanta 1
Belgrade 1
Bellante 1
Belvedere Spinello 1
Buccinasco 1
Totale 6.467
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 154
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 110
Candida guilliermondii fungemia in patients with hematologic malignancies. 108
Trichosporon beigelii fungaemia in an AIDS patient. 103
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 100
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 98
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 97
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 95
Antimicrobial activity of polycationic peptides 94
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 90
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 90
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 89
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 88
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 88
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 88
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 88
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 88
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 86
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 86
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 84
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 83
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 82
Epidemiology and microbiology of surgical wound infections. 81
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 81
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 80
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 79
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 79
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 78
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 78
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 77
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 77
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 77
Characterisation of candidemia in patients with recent surgery: A 7-year experience 77
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 76
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 75
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 75
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 75
Candidemia in the elderly: What does it change? 74
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 73
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 70
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 69
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 69
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 68
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 67
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 67
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 66
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 66
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 66
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 66
null 66
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 65
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 64
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 64
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 63
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 63
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 62
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 62
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 61
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 61
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 61
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 61
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. 60
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 60
EUCAST Technical Note on voriconazole. 60
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 60
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 59
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 58
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 58
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence. 58
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 58
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 58
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 58
EUCAST technical note on posaconazole. 57
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 57
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 56
Caspofungin in combination with amphotericin B against Candida glabrata. 56
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 56
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 56
Posaconazole prophylaxis in experimental systemic zygomycosis. 55
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 55
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 55
Caspofungin in combination with amphotericin B against Candida parapsilosis. 55
Electrophoretic karyotyping and antifungal susceptibility patterns of Candida parapsilosis clinical isolates causing deep and superficial fungal infections 55
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. 55
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 55
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 55
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 54
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 54
SIMIFF study: Italian fungal registry of mold infections in hematological and non-hematological patients. 54
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 54
EUCAST technical note on Amphotericin B 54
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 54
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 54
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 53
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 53
Inhibition of growth of Pneumocystis carinii by lactoferrins singly and in combination with pyrimethamine, clarithromycin and minocycline. 52
Treatment of murine cryptococcal meningitis with UR-9751 and UR-9746. 52
EUCAST technical note on fluconazole. 52
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 52
Efficacy of caspofungin against Aspergillus terreus 51
Totale 6.996
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.611
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.611
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.034 6 1 152 2 162 9 170 8 170 81 34 239
2020/20212.631 148 273 353 48 304 190 253 159 223 283 289 108
2021/20221.519 133 433 13 42 20 63 117 70 76 136 156 260
2022/20232.071 215 172 150 113 135 354 13 96 563 11 176 73
2023/20241.299 214 25 68 240 248 280 26 18 15 15 15 135
2024/2025175 175 0 0 0 0 0 0 0 0 0 0 0
Totale 10.163